Abstract 941P
Background
Immune checkpoint inhibitors (ICI) do not always show favorable outcomes in patients with advanced head and neck squamous cell carcinoma (HNSCC)). Once progressive disease (PD) occurs, the patient becomes deteriorated and ineligible for subsequent cytotoxic chemotherapy. Therefore, avoiding PD prior to ICI treatment is crucial. The purpose of this study is to identify the clinical features in patients who developed PD after ICI therapy.
Methods
We conducted a retrospective analysis of 125 patients with recurrent and/or metastatic (R/M) HNSCC treated with ICI between January 2013 and December 2018 at 11 medical centers in the Republic of Korea. We evaluated best response by RECIST1.1, progression-free survival and overall survival (OS). The associations between these outcomes and various clinical factors were analyzed.
Results
The median age was 57 years. 41.6% of the patients received ICIs as a third or later line of palliative chemotherapy. The complete response rate was 3.2%, partial response rate was 12.0%, stable disease rate was 25.6%, and the rate of PD was 54.4%. Hyper PD, defined as tumor growth kinetics ratio >2, was observed in 14.4%. The median PFS and OS were 2.3 months and 6.6 months, respectively. In univariate analysis, a neutrophil-to-lymphocyte ratio (NLR) >4, a sum of the target lesions >40 mm, and prior chemotherapy lines ≥2 were significant predictors of PD (P=0.014, 0.031, and 0.042, respectively). Multivariate logistic analysis showed high NLR, large tumor size, prior line of chemotherapy, type of ICI were independent predictors for PD. Furthermore, NLR >4 (HR 2.80, p<0.001), a poor performance status (ECOG≥2) (HR 4.76, p<0.001), and a sum of the target lesions >40mm (HR 1.70, p=0.048) were independently associated with poor OS. Patients who experienced PD had significantly shorter median OS (7.4 vs. 18.4 months, p<0.0071).
Conclusions
Our study identified clinical features that were associated with PD to ICIs in patients with R/M HNSCC. NLR, tumor size, and number of prior chemotherapy lines can serve as clinical predictors for the likelihood of PD for ICI. Clinicians can utilize these findings to personalize treatment plans and enhance patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bhumsuk Keam.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
942P - Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster session 12
944TiP - Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Presenter: Bálint Tamaskovics
Session: Poster session 12
1089P - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Presenter: Paolo Ascierto
Session: Poster session 12
1090P - Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Presenter: Sergio Martinez Recio
Session: Poster session 12
1092P - Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
Presenter: Manja Bloem
Session: Poster session 12
1093P - Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Presenter: Ahmad Tarhini
Session: Poster session 12
1094P - Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Presenter: Elizabeth Burton
Session: Poster session 12
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Presenter: Irene Reijers
Session: Poster session 12